A Phase I Study of XJ101 in Chinese Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-parallel intervention clinical study that will
include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects
will be assigned to one of four different dosage cohorts. Subjects in each cohort will
randomly be given experimental drug or a placebo.